Company news
Mynd Life Sciences Inc (CSE:MYND) news
Mynd Life Sciences Inc news releases on 6ix. Latest, Sep 30, 2026: Mynd.ai's Promethean Brand Launches On-Device AI Companion to Help Teachers Create Lesson…
Press releases & updates
Mynd.ai's Promethean Brand Launches On-Device AI Companion to Help Teachers Create Lesson Content in Seconds
September 30, 2026
MYND.AI REPORTS FIRST HALF 2026 RESULTS AS TURNAROUND GAINS MOMENTUM; ADJUSTED EBITDA IMPROVES 52%, OPERATING EXPENSES REDUCED 35%
August 27, 2026
Mynd.ai Unveils Privacy-First AI Tools to Improve Engagement in Classrooms and Workplaces
August 24, 2026
MYND.AI, INC. RECEIVES NYSE AMERICAN APPROVAL OF COMPLIANCE PLAN AND EXTENSION THROUGH DECEMBER 2027
August 17, 2026
Promethean showcases award-winning education solutions at ISTELive 2026
June 23, 2026
Mynd.ai Receives NYSE American Non-Compliance Notice
June 5, 2026
Mynd.ai Regains Compliance with NYSE American Filing Requirements Following Submission of Annual Report on Form 20-F
May 29, 2026
Promethean showcases award-winning workplace solutions at InfoComm 2026
May 28, 2026
Mynd.ai Receives Notice from NYSE American Regarding Late Filing of Annual Report on Form 20-F
May 22, 2026
Promethean named 'Company of the Year' at BETT Awards 2026
January 22, 2026
Promethean ActivSuite Expands Compatibility with ChromeOS Integration
January 20, 2026
Promethean Exhibits at Major Global Trade Shows in Early 2026
January 12, 2026
Mynd.ai Advances Platform Expansion and Ecosystem Monetization Strategy Through Planned Collaboration with Q101 Foundation
December 24, 2025
Mynd.ai's Promethean Brand Signs an Agreement with MAXHUB to Launch Teams-Certified Workplace Solution
December 15, 2025
Mynd.ai's Promethean Brand Announces Strategic Distribution Agreement with TD SYNNEX and Expands Midwich Collaboration to Accelerate U.S. GTM Strategy
December 2, 2025
Mynd.ai's Promethean Brand Advances AI Strategy with Launch of Augment Me Integration in Explain Everything®
November 17, 2025
Mynd.ai's Promethean brand Forges Strategic Relationship with Augment Me to Advance AI-Powered Learning
November 10, 2025
Mynd.ai Completes the Acquisition of Award-Winning AI Voice and Remote Control Technology
September 9, 2025
Mynd Announces 2025 First Half Results
August 27, 2025
Mynd.ai Enters into Agreement to Acquire Award-Winning AI Voice and Remote-Control Technology
August 26, 2025
Management Cease Trade Order Status Report
April 9, 2025
Management Cease Trade Order Granted
March 2, 2025
MYND Life Sciences Announces Shares for Debt Transaction
February 10, 2025
MYND Life Sciences Announces the Issuance of 4,000,001 Shares at $0.71/share
January 16, 2025
MYND Life Sciences Announces Successful Conclusion of Debenture Settlement Agreement and Leadership Transition
January 10, 2025
MYND Life Sciences Announces Strategic Debt Reduction and New Board Member Appointment
November 22, 2024
MYND Life Sciences Announces Proposed Share Issuance to Remove Debenture and $3.440 M in debt on business
November 11, 2024
MYND Life Sciences Announces New Director & Update on the Proposed Merger with Cava Healthcare Inc.
January 30, 2024
MYND Life Sciences Inc. Announces the Appointment of Mr. John Campbell as President and Chief Executive Officer
December 4, 2023
Dr. Lyle Oberg Appointment as Board Chair of Alberta Health Services and Executive Chair of MYND Life Sciences
December 4, 2023
MYND Life Sciences Inc. Announces Non-Binding LOI to enable merger with Cava Healthcare Inc.
October 25, 2023
MYND Life Sciences Announces Update on Payment Obligations Under Unsecured Convertible Debentures
September 11, 2023
MYND Life Sciences Inc. Has Management CTO Revoked
May 9, 2023
MYND Life Sciences Inc. Provides Default Status Report
April 25, 2023
MYND Life Sciences Inc. Announces Non-Binding MOU with German Based Oxygen Handel and Provides Default Status Report
March 27, 2023
MYND Life Sciences Inc. Achieves a Major Milestone and Provides Default Status Report
March 14, 2023
MYND Life Sciences Inc. Granted Management Cease Trade Order
March 1, 2023
MYND Life Sciences Announces the Sale of Leasehold Tenant Improvements and Health Canada Cannabis License
February 9, 2023
MYND Life Sciences announces funding for Psilocybin research on Neuroinflammation
November 30, 2021
MYND Diagnostics Commences Clinical Research on Multiple Sclerosis Biomarker Test
November 18, 2021
MYND Life Sciences Inc :. Announces RSU Grant
September 29, 2021
MYND Lifesciencs : Life Sciences Announces $3 Million Convertible Debenture Unit Offering
August 26, 2021
MYND Lifesciencs : Life Sciences Announces DTC Eligibility
August 11, 2021
MYND Lifesciencs : Life Sciences Announces Patent Applications for Depression and Neuropsychiatric Disorder Drugs
June 10, 2021
MYND Lifesciencs : Life Sciences announces Depression Biomarker Diagnostic Program
June 1, 2021
MYND Life Sciences Inc :. Establishes Scientific Advisory Board
May 31, 2021
MYND Life Sciences Inc :. Announces Public Listing on the Canadian Securities Exchange
May 27, 2021